Completed PHASE2 INTERVENTIONAL 4-arm NCT02360579

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144)

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

Sponsor: Iovance Biotherapeutics, Inc.

Conditions Metastatic Melanoma

Interventions Lifileucel

Updated 38 times since 2017 Last updated: Nov 21, 2025 Started: Sep 24, 2015 Primary completion: Oct 24, 2024 Completion: Oct 24, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02360579, this PHASE2 trial focuses on Metastatic Melanoma and remains completed. Sponsored by Iovance Biotherapeutics, Inc., it has been updated 38 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

38 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Jan 2026 [monthly]

Completed PHASE2
Dec 2024 — Sep 2025 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2

▶ Show 33 earlier versions

Aug 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Apr 2021 — Aug 2023 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE2
Feb 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2020 — Feb 2020 [monthly]

Recruiting PHASE2
Dec 2019 — Jan 2020 [monthly]

Recruiting PHASE2
Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE2
Oct 2019 — Nov 2019 [monthly]

Recruiting PHASE2
Aug 2019 — Oct 2019 [monthly]

Recruiting PHASE2
Jul 2019 — Aug 2019 [monthly]

Recruiting PHASE2
Jun 2019 — Jul 2019 [monthly]

Recruiting PHASE2
May 2019 — Jun 2019 [monthly]

Recruiting PHASE2
Apr 2019 — May 2019 [monthly]

Recruiting PHASE2
Mar 2019 — Apr 2019 [monthly]

Recruiting PHASE2

Status: Active Not Recruiting → Recruiting
Feb 2019 — Mar 2019 [monthly]

Active Not Recruiting PHASE2
Dec 2018 — Feb 2019 [monthly]

Active Not Recruiting PHASE2
Nov 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE2
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE2
Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE2
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Apr 2018 — May 2018 [monthly]

Recruiting PHASE2
Mar 2018 — Apr 2018 [monthly]

Recruiting PHASE2
Dec 2017 — Mar 2018 [monthly]

Recruiting PHASE2
Nov 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Aug 2017 — Nov 2017 [monthly]

Recruiting PHASE2
Jul 2017 — Aug 2017 [monthly]

Recruiting PHASE2
May 2017 — Jul 2017 [monthly]

Recruiting PHASE2
Mar 2017 — May 2017 [monthly]

Recruiting PHASE2
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Iovance Biotherapeutics, Inc.

Data source: Iovance Biotherapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Aviano, Italy , Barcelona, Spain , Bern, Switzerland , Buffalo, United States , Cambridge, United Kingdom , Candiolo, Italy , Dresden, Germany , Erlangen, Germany , Glasgow, United Kingdom and 40 more locations